Try a new search

Format these results:

Searched for:

in-biosketch:true

person:husais06

Total Results:

172


Cell-Free DNA: Proceed, but with Caution [Comment]

Crew, R John; Khairallah, Pascale; Husain, S Ali
PMID: 32778533
ISSN: 1533-3450
CID: 5867382

Tocilizumab for severe COVID-19 in solid organ transplant recipients: a matched cohort study [Case Report]

Pereira, Marcus R; Aversa, Meghan M; Farr, Maryjane A; Miko, Benjamin A; Aaron, Justin G; Mohan, Sumit; Cohen, David J; Husain, Syed A; Ratner, Lloyd E; Arcasoy, Selim; Uriel, Nir; Zheng, Elizabeth X; Fox, Alyson N; Tsapepas, Demetra S; Emond, Jean C; Verna, Elizabeth C
The safety and efficacy of tocilizumab for the treatment of severe respiratory symptoms due to COVID-19 remain uncertain, in particular among solid organ transplant (SOT) recipients. Thus, we evaluated the clinical characteristics and outcomes of 29 hospitalized SOT recipients who received tocilizumab for severe COVID-19, compared to a matched control group who did not. Among a total of 117 total SOT recipients hospitalized with COVID-19, 29 (24.8%) received tocilizumab. The 90-day mortality was significantly higher among patients who received tocilizumab (41%) compared to those who did not (20%, P = .03). When compared to control patients matched by age, hypertension, chronic kidney disease, and administration of high dose corticosteroids, there was no significant difference in mortality (41% vs 28%, P = .27), hospital discharge (52% vs 72%, P = .26), or secondary infections (34% vs 24%, P = .55). Among patients who received tocilizumab, there was also no difference in mortality based on the level of oxygen support (intubated vs not intubated) at the time of tocilizumab initiation. In this matched cohort study, tocilizumab appeared to be safe but was not associated with decreased 90-day mortality. Larger randomized studies are needed to identify whether there are subsets of SOT recipients who may benefit from tocilizumab for treatment of COVID-19.
PMID: 32946668
ISSN: 1600-6143
CID: 5867392

Content Coverage Evaluation of the OMOP Vocabulary on the Transplant Domain Focusing on Concepts Relevant for Kidney Transplant Outcomes Analysis

Cho, Sylvia; Sin, Margaret; Tsapepas, Demetra; Dale, Leigh-Anne; Husain, Syed A; Mohan, Sumit; Natarajan, Karthik
BACKGROUND:Improving outcomes of transplant recipients within and across transplant centers is important with the increasing number of organ transplantations being performed. The current practice is to analyze the outcomes based on patient level data submitted to the United Network for Organ Sharing (UNOS). Augmenting the UNOS data with other sources such as the electronic health record will enrich the outcomes analysis, for which a common data model (CDM) can be a helpful tool for transforming heterogeneous source data into a uniform format. OBJECTIVES:In this study, we evaluated the feasibility of representing concepts from the UNOS transplant registry forms with the Observational Medical Outcomes Partnership (OMOP) CDM vocabulary to understand the content coverage of OMOP vocabulary on transplant-specific concepts. METHODS:Two annotators manually mapped a total of 3,571 unique concepts extracted from the UNOS registry forms to concepts in the OMOP vocabulary. Concept mappings were evaluated by (1) examining the agreement among the initial two annotators and (2) investigating the number of UNOS concepts not mapped to a concept in the OMOP vocabulary and then classifying them. A subset of mappings was validated by clinicians. RESULTS:There was a substantial agreement between annotators with a kappa score of 0.71. We found that 55.5% of UNOS concepts could not be represented with OMOP standard concepts. The majority of unmapped UNOS concepts were categorized into transplant, measurement, condition, and procedure concepts. CONCLUSION:We identified categories of unmapped concepts and found that some transplant-specific concepts do not exist in the OMOP vocabulary. We suggest that adding these missing concepts to OMOP would facilitate further research in the transplant domain.
PMCID:7557323
PMID: 33027834
ISSN: 1869-0327
CID: 5867402

Major Variation across Local Transplant Centers in Probability of Kidney Transplant for Wait-Listed Patients

King, Kristen L; Husain, S Ali; Schold, Jesse D; Patzer, Rachel E; Reese, Peter P; Jin, Zhezhen; Ratner, Lloyd E; Cohen, David J; Pastan, Stephen O; Mohan, Sumit
BACKGROUND:Geographic disparities in access to deceased donor kidney transplantation persist in the United States under the Kidney Allocation System (KAS) introduced in 2014, and the effect of transplant center practices on the probability of transplantation for wait-listed patients remains unclear. METHODS:To compare probability of transplantation across centers nationally and within donation service areas (DSAs), we conducted a registry study that included all United States incident adult kidney transplant candidates wait listed in 2011 and 2015 (pre-KAS and post-KAS cohorts comprising 32,745 and 34,728 individuals, respectively). For each center, we calculated the probability of deceased donor kidney transplantation within 3 years of wait listing using competing risk regression, with living donor transplantation, death, and waiting list removal as competing events. We examined associations between center-level and DSA-level characteristics and the adjusted probability of transplant. RESULTS:<0.001). CONCLUSIONS:Large differences in the adjusted probability of deceased donor kidney transplantation persist under KAS, even between centers working with the same local organ supply. Probability of transplantation is significantly associated with organ offer acceptance patterns at transplant centers, underscoring the need for greater understanding of how centers make decisions about organs offered to wait-listed patients and how they relate to disparities in access to transplantation.
PMCID:7790218
PMID: 33037131
ISSN: 1533-3450
CID: 5867412

Impact of Deceased Donor Kidney Procurement Biopsy Technique on Histologic Accuracy

Husain, S Ali; Shah, Vaqar; Alvarado Verduzco, Hector; King, Kristen L; Brennan, Corey; Batal, Ibrahim; Coley, Shana M; Hall, Isaac E; Stokes, M Barry; Dube, Geoffrey K; Crew, R John; Perotte, Adler; Natarajan, Karthik; Carpenter, Dustin; Sandoval, P Rodrigo; Santoriello, Dominick; D'Agati, Vivette; Cohen, David J; Ratner, Lloyd; Markowitz, Glen; Mohan, Sumit
INTRODUCTION/BACKGROUND:The factors that influence deceased donor kidney procurement biopsy reliability are not well established. We examined the impact of biopsy technique and pathologist training on procurement biopsy accuracy. METHODS:We retrospectively identified all deceased donor kidney-only transplants at our center from 2006 to 2016 with both procurement and reperfusion biopsies performed and information available on procurement biopsy technique and pathologist (n = 392). Biopsies were scored using a previously validated system, classifying "suboptimal" histology as the presence of at least 1 of the following: glomerulosclerosis ≥11%, moderate/severe interstitial fibrosis/tubular atrophy, or moderate/severe vascular disease. We calculated relative risk ratios (RRR) to determine the influence of technique (core vs. wedge) and pathologist (renal vs. nonrenal) on concordance between procurement and reperfusion biopsy histologic classification. RESULTS: = 0.14) biopsies. Overall, 34% of kidneys had discordant classification on procurement versus reperfusion biopsy. Neither biopsy technique nor pathologist training was associated with concordance between procurement and reperfusion histology, but a larger number of sampled glomeruli was associated with a higher likelihood of concordance (adjusted RRR = 1.12 per 10 glomeruli, 95% confidence interval = 1.04-1.22). CONCLUSIONS:Biopsy technique and pathologist training were not associated with procurement biopsy histologic accuracy in this retrospective study. Prospective trials are needed to determine how to optimize procurement biopsy practices.
PMCID:7609887
PMID: 33163711
ISSN: 2468-0249
CID: 5867422

High rate of renal recovery in survivors of COVID-19 associated acute renal failure requiring renal replacement therapy

Stevens, Jacob S; King, Kristen L; Robbins-Juarez, Shelief Y; Khairallah, Pascale; Toma, Katherine; Alvarado Verduzco, Hector; Daniel, Emily; Douglas, Denzil; Moses, Andrew A; Peleg, Yonatan; Starakiewicz, Piotr; Li, Miah T; Kim, Daniel W; Yu, Kathleen; Qian, Long; Shah, Vaqar H; O'Donnell, Max R; Cummings, Matthew J; Zucker, Jason; Natarajan, Karthik; Perotte, Adler; Tsapepas, Demetra; Krzysztof, Kiryluk; Dube, Geoffrey; Siddall, Eric; Shirazian, Shayan; Nickolas, Thomas L; Rao, Maya K; Barasch, Jonathan M; Valeri, Anthony M; Radhakrishnan, Jai; Gharavi, Ali G; Husain, S Ali; Mohan, Sumit
INTRODUCTION:A large proportion of patients with COVID-19 develop acute kidney injury (AKI). While the most severe of these cases require renal replacement therapy (RRT), little is known about their clinical course. METHODS:We describe the clinical characteristics of COVID-19 patients in the ICU with AKI requiring RRT at an academic medical center in New York City and followed patients for outcomes of death and renal recovery using time-to-event analyses. RESULTS:Our cohort of 115 patients represented 23% of all ICU admissions at our center, with a peak prevalence of 29%. Patients were followed for a median of 29 days (2542 total patient-RRT-days; median 54 days for survivors). Mechanical ventilation and vasopressor use were common (99% and 84%, respectively), and the median Sequential Organ Function Assessment (SOFA) score was 14. By the end of follow-up 51% died, 41% recovered kidney function (84% of survivors), and 8% still needed RRT (survival probability at 60 days: 0.46 [95% CI: 0.36-0.56])). In an adjusted Cox model, coronary artery disease and chronic obstructive pulmonary disease were associated with increased mortality (HRs: 3.99 [95% CI 1.46-10.90] and 3.10 [95% CI 1.25-7.66]) as were angiotensin-converting-enzyme inhibitors (HR 2.33 [95% CI 1.21-4.47]) and a SOFA score >15 (HR 3.46 [95% CI 1.65-7.25). CONCLUSIONS AND RELEVANCE:Our analysis demonstrates the high prevalence of AKI requiring RRT among critically ill patients with COVID-19 and is associated with a high mortality, however, the rate of renal recovery is high among survivors and should inform shared-decision making.
PMCID:7769434
PMID: 33370368
ISSN: 1932-6203
CID: 5867442

Cystatin C- Versus Creatinine-Based Assessment of Renal Function and Prediction of Early Outcomes Among Patients With a Left Ventricular Assist Device

Pinsino, Alberto; Mondellini, Giulio M; Royzman, Eugene A; Hoffman, Katherine L; D'Angelo, Debra; Mabasa, Melissa; Gaudig, Antonia; Zuver, Amelia M; Masoumi, Amirali; Garan, A Reshad; Mohan, Sumit; Husain, Syed A; Toma, Katherine; Faillace, Robert T; Giles, Jon T; Takeda, Koji; Takayama, Hiroo; Naka, Yoshifumi; Topkara, Veli K; Demmer, Ryan T; Radhakrishnan, Jai; Colombo, Paolo C; Yuzefpolskaya, Melana
BACKGROUND:Estimated glomerular filtration rate (eGFR) based on serum creatinine (sCr) improves early after left ventricular assist device (LVAD) implantation but subsequently declines. Although sCr is a commonly accepted clinical standard, cystatin C (CysC) has shown superiority in assessment of renal function in disease states characterized by muscle wasting. Among patients with an LVAD, we aimed to (1) longitudinally compare CysC-eGFR and sCr-eGFR, (2) assess their predictive value for early postoperative outcomes, and (3) investigate mechanisms which might explain potential discrepancies. METHODS:A prospective cohort (n=116) with CysC and sCr concurrently measured at serial time points, and a retrospective cohort (n=91) with chest computed tomography performed within 40 days post-LVAD were studied. In the prospective cohort, the primary end point was a composite of in-hospital mortality, renal replacement therapy, or severe right ventricular failure. In the retrospective cohort, muscle mass was estimated using pectoralis muscle area indexed to body surface area (pectoralis muscle index). RESULTS:=0.004). CONCLUSIONS:Initial improvement in sCr-eGFR is likely due to muscle wasting following LVAD surgery. CysC may improve assessment of renal function and prediction of early postoperative outcomes in patients with an LVAD.
PMID: 31959016
ISSN: 1941-3297
CID: 5445032

C4 article: Challenges and solutions to appropriate and timely medication access in transplantation in the United States

Alvey, N R; Barnes, D; Boesken, T A; Bowman, L; Campara, M; Chan, C; Cochrane, A B; Cross, R P; Crowther, B; Cunningham, K; Dantzler, T; Dao, A; Doligalski, C; Decker, M D; Fowler, K J; Georgiadis, C; Giorgakis, E; Golebiewska, J; Hall, R; Hanners, E; Harris, M T; Humrickhouse, R; Husain, S A; Jandovitz, N; Kaiser, T E; Kane, C; Karpen, S R; Khalil, K; Klein, K; Krieger, D M; Kutzler, H L; Laub, M R; Lee, R -A M; Lerma, E; Liverman, R; Maldonado, A Q; Masters, B M; McCann, A; McKnight, C E; Melaragno, J I; Mikolay, J; Morgan, A; Morris, H A; Chandran, M M; Moy, K; Nelson, J; Nguyen, C Q; Padikkala, B; Park, J M; Pica, C; Pilch, N A; Salas, M A P; Potter, L; Queen, C; Ravichandran, B R; Rendulic, T; Sammons, C; Schmidt, L; Schmiedeskamp-Rahe, M; Schnelle, K; Schulte, J; Schwab, J; Schwartz, J; Shah, R; Shaikh, S A; Shao, S H; Sharma, P; Sholkamy, A; Simpson, M C; Singh, N; Snyder, H S; Sparkes, T; Spinner, M L; Taber, D J; Tan, T; Tantisattamo, E; Trofe-Clark, J; Truax, C; Tsapepas, D; Tsui, J; Valdepenas, B T; Verghese, P; Wang, U; Westphal, S G; Whisler, R; Woodside, K J; Yabu, J M
EMBASE:2004118762
ISSN: 1600-6143
CID: 5083112

Pilot Study of Return of Genetic Results to Patients in Adult Nephrology

Nestor, Jordan G; Marasa, Maddalena; Milo-Rasouly, Hila; Groopman, Emily E; Husain, S Ali; Mohan, Sumit; Fernandez, Hilda; Aggarwal, Vimla S; Ahram, Dina F; Vena, Natalie; Bogyo, Kelsie; Bomback, Andrew S; Radhakrishnan, Jai; Appel, Gerald B; Ahn, Wooin; Cohen, David J; Canetta, Pietro A; Dube, Geoffrey K; Rao, Maya K; Morris, Heather K; Crew, Russell J; Sanna-Cherchi, Simone; Kiryluk, Krzysztof; Gharavi, Ali G
BACKGROUND AND OBJECTIVES:Actionable genetic findings have implications for care of patients with kidney disease, and genetic testing is an emerging tool in nephrology practice. However, there are scarce data regarding best practices for return of results and clinical application of actionable genetic findings for kidney patients. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS:We developed a return of results workflow in collaborations with clinicians for the retrospective recontact of adult nephrology patients who had been recruited into a biobank research study for exome sequencing and were identified to have medically actionable genetic findings. RESULTS:Using this workflow, we attempted to recontact a diverse pilot cohort of 104 nephrology research participants with actionable genetic findings, encompassing 34 different monogenic etiologies of nephropathy and five single-gene disorders recommended by the American College of Medical Genetics and Genomics for return as medically actionable secondary findings. We successfully recontacted 64 (62%) participants and returned results to 41 (39%) individuals. In each case, the genetic diagnosis had meaningful implications for the patients' nephrology care. Through implementation efforts and qualitative interviews with providers, we identified over 20 key challenges associated with returning results to study participants, and found that physician knowledge gaps in genomics was a recurrent theme. We iteratively addressed these challenges to yield an optimized workflow, which included standardized consultation notes with tailored management recommendations, monthly educational conferences on core topics in genomics, and a curated list of expert clinicians for patients requiring extranephrologic referrals. CONCLUSIONS:Developing the infrastructure to support return of genetic results in nephrology was resource-intensive, but presented potential opportunities for improving patient care. PODCAST:This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2020_04_16_12481019.mp3.
PMCID:7269209
PMID: 32299846
ISSN: 1555-905x
CID: 4994162

Early Outcomes of Outpatient Management of Kidney Transplant Recipients with Coronavirus Disease 2019

Husain, S Ali; Dube, Geoffrey; Morris, Heather; Fernandez, Hilda; Chang, Jae-Hyung; Paget, Kathryn; Sritharan, Sharlinee; Patel, Shefali; Pawliczak, Olga; Boehler, Mia; Tsapepas, Demetra; Crew, R John; Cohen, David J; Mohan, Sumit
BACKGROUND AND OBJECTIVES:Outcomes of kidney transplant recipients diagnosed with coronavirus disease 2019 as outpatients have not been described. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS:We obtained clinical data for 41 consecutive outpatient kidney transplant recipients with known or suspected coronavirus disease 2019. Chi-squared and Wilcoxon rank sum tests were used to compare characteristics of patients who required hospitalization versus those who did not. RESULTS:=0.02), but there were no other differences between groups. CONCLUSIONS:In an early cohort of outpatient kidney transplant recipients with known or suspected coronavirus disease 2019, many had symptomatic resolution without requiring hospitalization.
PMID: 32423908
ISSN: 1555-905x
CID: 4994172